Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012.

scientific article published on 8 February 2018

Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/CAS.13480
P932PMC publication ID5834807
P698PubMed publication ID29284202

P50authorHyun Cheol ChungQ59647646
Makoto TaharaQ89747698
Yung-Jue BangQ16180903
P2093author name stringKenichi Takahashi
Jonathan D Cheng
Bhumsuk Keam
Yasuhisa Hasegawa
Chia-Chi Lin
Kei Muro
P2860cites workAntitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.Q38959172
Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b studyQ39084242
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.Q39193035
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckQ43164702
Pemetrexed in combination with cisplatin versus cisplatin monotherapy in East Asian patients with recurrent or metastatic head and neck cancer: Results of an exploratory subgroup analysis of a phase III trialQ44523490
Analysis of risk factors of predictive local tumor control in oral cavity cancerQ80424493
Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trialQ87633710
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in MelanomaQ27860650
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012Q27861047
The synergistic effect of chemical carcinogens enhances Epstein-Barr virus reactivation and tumor progression of nasopharyngeal carcinoma cellsQ28483778
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialQ29620814
Pembrolizumab for the treatment of non-small-cell lung cancerQ29620851
Platinum-based chemotherapy plus cetuximab in head and neck cancerQ33381094
Epidemiology and Inequality in the Incidence and Mortality of Nasopharynx Cancer in AsiaQ36239931
Cancer risk associated with alcohol and tobacco use: focus on upper aero-digestive tract and liver.Q36764761
Treatment of recurrent metastatic head and neck cancer: focus on cetuximabQ37218978
Consensus recommendations for management of head and neck cancer in Asian countries: a review of international guidelines.Q38119732
State-of-the-art and emerging treatment options in the management of head and neck cancer: news from 2013.Q38211309
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.Q38393045
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trialQ38829062
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trialQ38849759
Global Epidemiology of Head and Neck Cancers: A Continuing Challenge.Q38860198
P433issue3
P921main subjectpembrolizumabQ13896859
head and neck squamous cell carcinomaQ18348812
P304page(s)771-776
P577publication date2018-02-08
P1433published inCancer ScienceQ326125
P1476titlePembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012
P478volume109